Skip to main content
SpringerLink
Log in

A new opportunity for thalidomide? Further randomised controlled trial are necessary

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Annas GJ, Elias S (1999) Thalidomide and the titanic: reconstructing the technology tragedies of the twentieth century. Am J Public Health 89:98–101

    CAS  PubMed  Google Scholar 

  2. Eriksson T, Bjorkman S, Hoglund P (2001) Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 57:365–376

    Article  CAS  PubMed  Google Scholar 

  3. Matthews, SJ, McCoy C (2003) Thalidomide: a review of approved and investigational uses. Clin Ther 25(2):342–395

    Article  CAS  PubMed  Google Scholar 

  4. Franks ME, Macpherson GR, Figg WD (2004) Thalidomide. Lancet 363:1802–1811

    Article  CAS  PubMed  Google Scholar 

  5. Bessmertny O, Pham T (2002) Thalidomide use in pediatric patients. Ann Pharmacother 36(3):521–525

    Article  PubMed  Google Scholar 

  6. Facchini S, Candusso M, Martelossi S, Liubich M, Panfili E, Ventura A (2001) Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr 32(2):178–81

    Article  CAS  PubMed  Google Scholar 

  7. Marchetti F, Trevisiol C, Ventura A (2002) Intestinal involvement in children with Bechet’s disease. Lancet 359:2115

    Article  Google Scholar 

  8. Ahmed M, El-Hadi S, Jenkins HR (2003) Thalidomide in Crohn disease and the risk of peripheral neuropathy. J Pediatr Gastroenterol Nutr 37(4):522

    CAS  PubMed  Google Scholar 

  9. Rutgeerts P, Van Assche G, Vermeire S (2004) Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126:1593–1610

    Article  CAS  PubMed  Google Scholar 

  10. European Commission (2002) Better medicines for children. Proposed regulatory actions on paediatric medical products. Brussels. Available at: http://pharmacos.eudra.org/F2/pharmacos/docs/Doc2002/feb/cd_pediatrics_en.pdf.2002

  11. Zeldis JB, Williams BA, Thomas SD, Elsayed ME (1999) S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21:319–30

    Article  CAS  PubMed  Google Scholar 

  12. Haffner ME, Whitley J, Moses M (2002) Two decades of orphan product development. Nat Rev 1:821–825 http://www.nature.com/reviews/drugdisc

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatrics, Institute of Child Health, IRCCS Burlo Garofolo, University of Trieste, Via dell’Istria 65/1, 34100, Trieste, Italy

    Federico Marchetti, Marzia Lazzerini & Alessandro Ventura

Authors
  1. Federico Marchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marzia Lazzerini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Ventura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Federico Marchetti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marchetti, F., Lazzerini, M. & Ventura, A. A new opportunity for thalidomide? Further randomised controlled trial are necessary. Eur J Clin Pharmacol 60, 607–608 (2004). https://doi.org/10.1007/s00228-004-0819-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0819-z

Keywords

Search

Navigation